Fast, automated & reproducible analysis of biopharmaceutical stability for the regulated environment
Advancing biological molecules through the development pipeline is no simple or speedy process. The stability of biotherapeutic molecules and formulations is key to their progression, and must be assessed and reviewed throughout development, from candidate selection all the way through to batch-to-batch comparability or biosimilarity assessment….and beyond! What’s needed is simple, objective data that you can trust.
At Malvern, we have designed a stability characterization technology for the regulated environment that is not only easy-to-use, but also delivers artifact-free data with unrivalled detail and reproducibility, giving you absolute confidence in your decisions.
We are proud to unveil the new MicroCal PEAQ–DSC – the ultimate solution for every laboratory involved in the assessment of biomolecular stability and biocomparability – one technology to provide high–throughput, automated operation for all users.
Please join us on February 21st 2017, and be one of the first to see how the future of protein stability analysis has been transformed.
.
Presented by
Dr. Ronan O’Brien,
Head of Business Development – Malvern MicroCal
Ronan has a PhD in biophysical chemistry and spent many years working in the area of label-free interaction analysis, a discipline in which he has published widely, including contributions to a number of educational textbooks. He carried out his post-doctoral research with Professor Julian Sturtevant at Yale University and Professor John Ladbury at University College London, before joining MicroCal as an applications expert in 2001. Since then he has held a number of roles including Scientific Marketing Manager and Head of R&D before taking on his current position as Head of Business Development for the MicroCal product group at Malvern Instruments.
